plans to promote to the United Nations Kids’s Fund as much as 4 million therapy programs of its Covid-19 capsule Paxlovid, which is able to go to 95 low- and middle-income international locations, as a part of the corporate’s effort to expand access to the pill past rich international locations.
Pfizer mentioned Tuesday that Afghanistan, Pakistan and Zimbabwe are among the many international locations the place Unicef will distribute the easy-to-use capsule.
A Pfizer spokeswoman mentioned the corporate is charging Unicef a “not-for-profit worth,” however declined to reveal it.
Pfizer mentioned it might begin delivery tablets in April to international locations the place Paxlovid is allowed, and it expects extra provides to change into accessible all year long. The corporate mentioned it expects to supply 120 million therapy programs by the top of 2022.
“Supplying to Unicef is a crucial a part of our complete technique to speed up entry to Paxlovid to deal with Covid-19 an infection as shortly as doable and at an reasonably priced worth,” Pfizer Chief Govt
Final yr, Pfizer agreed to license Paxlovid to the United Nations-backed Medicines Patent Pool, to permit different drugmakers to fabricate the capsule to be used in lower-income international locations, together with in sub-Saharan Africa.
Paxlovid is an antiviral therapy used to assist velocity restoration from Covid-19 in individuals with gentle to reasonable signs however who’re at excessive threat of dangerous circumstances. In clinical trials, the drug diminished the chance of hospitalization or dying by 89% in contrast with a placebo.
The drug, which is taken together with one other antiviral capsule, requires sufferers to take six tablets each day over 5 days, and is regarded as simpler to distribute than monoclonal antibody medication, which require a one-time infusion given by a healthcare skilled.
Pfizer has agreements to promote 38.8 million Paxlovid therapy programs around the globe, not together with the 4 million programs disclosed on Tuesday, in response to data from the Duke Global Health Innovation Center. Practically three-quarters of the programs are promised to high-income international locations, in response to the Duke knowledge.
The Food and Drug Administration authorized Paxlovid for emergency use final December. Pfizer has agreed to promote 10 million therapy programs to the U.S. authorities for $5.29 billion, or $529 per course.
To date, the U.S. has distributed about 1.04 million Paxlovid therapy programs, in response to knowledge from the Division of Well being and Human Providers.
Write to Joseph Walker at email@example.com
Copyright ©2022 Dow Jones & Firm, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8